摘要
目的系统评价格列美脲与格列苯脲治疗2型糖尿病的疗效。方法计算机检索PubMed、Ov-id、中国知网(CNKI)、万方、维普、中国生物医学文献数据库(CBM)等数据库建库截至2010年12月的有关文献。按Cochrane系统评价的方法评价纳入研究质量,使用Review Manager 4.2软件进行Meta分析。结果本研究共纳入9个前瞻性随机对照试验(RCT)进行分析。研究结果显示,格列美脲在降低糖化血红蛋白、空腹及餐后血糖、胆固醇、甘油三酯方面与格列苯脲差异无统计学意义(P>0.05);在相同血糖水平下,格列美脲空腹及餐后胰岛素升高的程度明显低于格列苯脲(P<0.05),低血糖发生率低于格列苯脲(P<0.05),在降低体重指数方面优于格列苯脲(P<0.05)。结论与格列苯脲相比,格列美脲不仅可以降低血糖,还可以改善胰岛素抵抗及减轻体重,低血糖发生率低,是有效安全地治疗2型糖尿病的药物。
Objective To assess therapeutic efficacy of glimepiride vs glibenclamide in treatment of type 2 diabetes mellitus （T2DM）. Methods We searched medical literatures in several databases including the PubMed, CNKI, Wanfang and VIP databases. The quality of the studies was evaluated according to criteria in Cochrane systematic reviews. Meta-analysis of these studies was completed with the Review Manager （ version 4. 2 ） software package. Results Nine prospective RCTs were included in the analysis. The results showed that there were no differences between two groups in reducing glycosylated hemoglobin,fasting and postprandial plasma glucose, cholesterol and triglyceride （ P 〉 0. 05 ）. In patients with the same glucose level, glimepiride was associated with significantly less increase in fasting and postprandial plasma insulin （ P 〈 0. 05 ） , and lower incidence of hypoglycemia as compared with glibenclamide （ P 〈 0.05 ）. In addition, glimepiride showed better performance than glibenclamide in reducing BMI （P 〈 0. 05）. Conclusion Compared with glibenclamide, glimepiride is as potent in reducing blood glucose and shows additional benefits with improved insulin resistance and lower incidence of BMI. Therefore, glimepiride is a safe and effective agent for treatment of type 2 diabetes mellitus.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2011年第11期862-864,共3页
Chinese Journal of Practical Internal Medicine
关键词
格列美脲
格列苯脲
2型糖尿病
glimepiride
glibenclamide
type 2 diabetes mellitus
